Since 1987, SEC Technology has been providing a specialist recruitment service to European businesses within the information technology skill set. Using over 25 years’ expertise and sector knowledge, we pride ourselves on pro-actively matching niche professionals with hard-to-fill positions within ERP, CRM, IT Infrastructure, Software Development and Project Management.
We provide a consultative service dedicated to getting to know all about candidates and clients alike. We pride ourselves on a responsive approach, catering for the individual needs of every client and advising and preparing candidates in line with the continual changes of the marketplace.
We pride ourselves on building long-term relationships that benefit clients and candidates alike. For clients, we combine industry knowledge with an understanding of your company culture to deliver the very best qualified candidates who are also the right fit for your organisation. And for candidates, our consultative approach means we can proactively advise you on choices for your next role and we will stay in contact post-placement. We strive to ensure that SEC Technology becomes your consultancy of choice when planning your next career move or sourcing a new contract role.
SEC latest news
SEC Pharma Joins Forces with IAOCRAugust 12, 2014 - SEC Pharma is delighted to announce that we have joined forces with IAOCR to provide innovative solutions to recruiting, developing and retaining clinical research professionals. IAOCR provides training, accreditation and consultancy services to pharmaceutical, biotech and clinical research organisations and is one of the only organisations in the world to provide independently verified and
Roche to Acquire Santaris PharmaAugust 7, 2014 - Roche has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company as part of its plan to expand discovery and development of RNA-targeting medicines. Santaris has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics. This new class of medicines has the potential to address